Syros Pharmaceuticals マネジメント

マネジメント基準チェック /24

Syros Pharmaceuticalsの CEO はConley Cheeで、 Dec2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 1.04Mで、 46%給与と54%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.49%を直接所有しており、その価値は€ 36.86K 。経営陣と取締役会の平均在任期間はそれぞれ2.6年と11.6年です。

主要情報

Conley Chee

最高経営責任者

US$1.0m

報酬総額

CEO給与比率	46.0%
CEO在任期間	less than a year
CEOの所有権	0.5%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	11.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Syros Pharmaceuticals の収益と比較して、Conley Chee の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$98m
Jun 30 2024	n/a	n/a	-US$132m
Mar 31 2024	n/a	n/a	-US$144m
Dec 31 2023	US$1m	US$479k	-US$165m

報酬と市場: Conleyの総報酬 ($USD 1.04M ) は、 German市場 ($USD 471.14K ) の同規模の企業の平均を上回っています。

報酬と収益: Conleyの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Conley Chee (54 yo)

less than a year

在職期間

US$1,041,697

報酬

Mr. Conley Chee serves as President, Chief Executive Officer & Director at Syros Pharmaceuticals, Inc. since December 02, 2023. He served as Chief Commercial Officer at Syros Pharmaceuticals, Inc. since Se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	no data	US$82.15k	0.040% € 3.0k
Jason Haas	Chief Financial Officer	3.1yrs	US$833.02k	0% € 0
David Roth	Chief Medical Officer	8.9yrs	US$876.53k	0% € 0
James Bradner	Founder	no data	データなし	データなし
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	no data	データなし	データなし
Gerald Quirk	Chief Legal & Compliance Officer and Chief Business Officer	2.1yrs	US$1.46m	0% € 0
Lisa Roberts	Vice President of Human Resources	1.8yrs	データなし	データなし
Kristin Stephens	Chief Development Officer	4.4yrs	データなし	0% € 0

2.6yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: 0S90の経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Conley Chee	CEO, President & Director	less than a year	US$1.04m	0.49% € 36.9k
Richard Young	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	US$82.15k	0.040% € 3.0k
Nathanael Gray	Scientific Founder & Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Peter Karl Wirth	Independent Chairman	7.8yrs	US$110.40k	0.060% € 4.5k
Mark Murcko	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Nancy Simonian	Director	11.6yrs	US$1.49m	0.66% € 49.5k
Gerard Evan	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Scott Biller	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Bradley Bernstein	Member of Scientific Advisory Board	no data	データなし	データなし
Stefan Knapp	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Aviv Regev	Member of Scientific Advisory Board	11.6yrs	データなし	データなし
Chris Vakoc	Member of Scientific Advisory Board	11.6yrs	データなし	データなし

11.6yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: 0S90の取締役会は経験豊富で経験豊富です ( 11.6年の平均在任期間)。

Syros Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Chief Financial Officer recently bought €146k worth of stock

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

Insufficient new directors

Insider recently bought €108k worth of stock

Insufficient new directors

Recent updates

New major risk - Revenue and earnings growth

Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Third quarter 2024 earnings released: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Chief Financial Officer recently bought €146k worth of stock

New minor risk - Profitability

Syros Pharmaceuticals Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

First half 2024 earnings released: US$0.69 loss per share (vs US$2.15 loss in 1H 2023)

Syros Pharmaceuticals, Inc. to Report Q2, 2024 Results on Jul 31, 2024

New minor risk - Profitability

First quarter 2024 earnings released: US$0.095 loss per share (vs US$0.85 loss in 1Q 2023)

Syros Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$5.81 loss per share (vs US$7.49 loss in FY 2022)

Syros Pharmaceuticals, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Forecast to breakeven in 2026

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $44.999989 million.

Syros Pharmaceuticals Announces Encouraging Initial Data from Randomized Select-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine

Third quarter 2023 earnings released: US$1.43 loss per share (vs US$3.21 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Syros Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Syros Pharmaceuticals, Inc. Announces Chief Executive Officer Changes, Effective December 2, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: US$1.30 loss per share (vs US$5.40 loss in 2Q 2022)

Syros Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Syros Pharmaceuticals Presents Data from Phase 1/1b Clinical Trial of SY-5609 in Advanced Solid Tumors at ASCO Annual Meeting

First quarter 2023 earnings released: US$0.85 loss per share (vs US$3.99 loss in 1Q 2022)

Full year 2022 earnings released: US$7.49 loss per share (vs US$13.84 loss in FY 2021)

Syros Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Higher-Risk Myelodysplastic Syndrome

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with Rara Gene Overexpression, Supporting Ongoing Clinical Development in Aml and Mds

Syros Presents Safety Lead-In Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

Third quarter 2022 earnings released: US$3.21 loss per share (vs US$4.14 loss in 3Q 2021)

Insufficient new directors

Syros Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Syros Pharmaceuticals Regains Compliance with Minimum Bid Requirement

Insider recently bought €108k worth of stock

Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS) completed the acquisition of Tyme Technologies, Inc. (NasdaqCM:TYME) from a group of shareholders.

Second quarter 2022 earnings released: US$0.54 loss per share (vs US$0.36 loss in 2Q 2021)

Syros Pharmaceuticals, Inc. Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS

Syros Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Tyme Technologies, Inc. (NasdaqCM:TYME) entered into a definitive merger agreement to acquire Tyme Technologies, Inc. (NasdaqGS:SYRS) from Adage Capital Partners, L.P., Samsara Biocapital, L.P., Jalaa Equities, L.P., Flagship Pioneering Fund VII, CVI Investments, Inc. and others for $67.6 million.

First quarter 2022 earnings released: US$0.40 loss per share (vs US$0.23 loss in 1Q 2021)

Syros Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Syros Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Syros Pharmaceuticals, Inc. Presents New Preclinical Data on Its Cdk12 Inhibitor Program At American Association for Cancer Research (Aacr) Annual Meeting 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Syros Pharmaceuticals Provides Update on its Clinical Development Programs and Outlined its Strategic Priorities and Upcoming Expected Milestones

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.43 loss in 3Q 2020)

Syros Pharmaceuticals, Inc. Presents New Data from Phase 1 Trial of Sy-5609 and Details Three-Pronged Combination Strategy to Advance Sy-5609 in Solid Tumors and Blood Cancer

Syros Pharmaceuticals Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML

Second quarter 2021 earnings released: US$0.36 loss per share (vs US$0.38 loss in 2Q 2020)

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.39 loss in 1Q 2020)

New 90-day low: €6.60

Full year 2020 earnings released: US$1.83 loss per share (vs US$1.88 loss in FY 2019)

Revenue beats expectations

Syros Pharmaceuticals, Inc. announced that it has received $20 million in funding from Oxford Finance LLC

New 90-day high: €8.75

Syros Pharmaceuticals, Inc. Announces the New Clinical Data from its Phase 2 Trial Evaluating SY-1425

Revenue beats expectations

Third quarter 2020 earnings released: US$0.43 loss per share

Syros Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day low: €6.50

マネジメント基準チェック /24